Clozapine is well-known for successful use in schizophrenic patients treatment resistant to other antipsychotics. However, even with clozapine, 25% of schizophrenic patients are not in remission. Recently, as adjunctive treatment with clozapine, electroconvulsive therapy has been reported to be an effective and safe adjunctive treatment. We report a Japanese schizophrenic woman who was not in remission with clozapine alone but with both clozapine and electroconvulsive therapy.
Antipsychotic Agents ; Asian Continental Ancestry Group* ; Clozapine* ; Electroconvulsive Therapy* ; Female ; Humans ; Lithium ; Schizophrenia*

Purpose: Determination of optimal treatment strategies for HER2-positive advanced gastric cancer (AGC) in randomized trials is necessary despite difficulties in direct comparison between trastuzumab deruxtecan (T-DXd) and nivolumab as third or later-line treatments. Materials and Methods: This single-institution, retrospective study aimed to describe the real-world efficacy and safety of T-DXd and nivolumab as ≥ third line treatments for HER2-positive AGC between March 2016 and May 2022. Overall, 58 patients (median age, 64 years;69% male) were eligible for the study (T-DXd group, n=20; nivolumab group, n=38). Results: Most patients exhibited a HER2 3+ status (72%) and presented metastatic disease at diagnosis (66%). The response rates of 41 patients with measurable lesions in the T-DXd and nivolumab groups were 50% and 15%, respectively. The T-DXd and nivolumab groups had a median progression-free survival of 4.8 months (95% confidence interval [CI], 3.3, 7.0) and 2.3 months (95% CI, 1.5, 3.5), median overall survival (OS) of 10.8 months (95% CI, 6.9, 23.8) and 11.7 months (95% CI, 7.6, 17.1), and grade 3 or greater adverse event rates of 50% and 2%, respectively. Overall, 64% patients received subsequent treatment. Among 23 patients who received both regimens, the T-DXd–nivolumab and nivolumab–T-DXd groups had a median OS of 14.0 months (95% CI, 5.0, not reached) and 19.3 months (95% CI, 9.5, 25.1), respectively. Conclusions T-DXd and nivolumab showed distinct efficacy and toxicity profiles as ≥ third line treatments for HER2-positive AGC. Considering the distinct features of each regimen, they may help clinicians personalize optimal treatment approaches for these patients.

The purpose of the present study was to examine the validity and reliability of the stages of change for sedentary behavior scale among workers. The participants were 2400 Japanese workers aged 20-59 years (male: 50.0%, mean age: 40.4±10.8 years) recruited from research company. With an internet-based survey, the stages of change for sedentary behavior, total sitting time (min/day), socio-demographic characteristics, health-related characteristics and work-related characteristics were obtained. “Too much sitting” was defined as sitting or lying down for a total of 8 hours or more per day on average. Participants were categorized into one of 5 stages based on their present status for “too much sitting” and motivational readiness for reducing sedentary behavior. For the criterion validity, a one-way analysis of variance was utilized to compare the total sitting time among the 5 stages. To assess the test-retest reliability, randomly-selected 200 workers answered the scale again two weeks later. Then, the Kappa index (k) was calculated. As results, the means of total sitting time were significantly distinguished across the stages [F (4, 2395) =111.5, p<0.001, η2=0.16]. Participants in early stages (precontemplation, contemplation, preparation) had significantly longer sitting time than those in the Maintenance (Precontemplation>Contemplation, Preparation>Action, Maintenance) (p<0.001). The scale to assess the readiness to reduce sedentary time has shown good 2-week test-retest reliability (k=0.64). These results suggest that the developed scale presented good validity and reliability to assess the motivational readiness for reducing prolonged sedentary behavior among Japanese workers.